2008
DOI: 10.1080/09505430701872814
|View full text |Cite
|
Sign up to set email alerts
|

Standardizing the Unknown: Practicable Pluripotency as Doable Futures

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
33
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(33 citation statements)
references
References 13 publications
0
33
0
Order By: Relevance
“…(Similar definitional issues have complicated efforts to standardize stem cell lines, see e.g. Eriksson & Webster 2008.) At present, it is far easier to make a BioBrick than to characterize one; agreeing on what to measure in order to characterize a biological part is acknowledged as a crucial issue for the progress of the field (Arkin, 2008), but has received less community attention to date than the issue of what design standard(s) BioBricks should conform to.…”
Section: Negotiating Epistemic Value Through Biobrick Designmentioning
confidence: 99%
“…(Similar definitional issues have complicated efforts to standardize stem cell lines, see e.g. Eriksson & Webster 2008.) At present, it is far easier to make a BioBrick than to characterize one; agreeing on what to measure in order to characterize a biological part is acknowledged as a crucial issue for the progress of the field (Arkin, 2008), but has received less community attention to date than the issue of what design standard(s) BioBricks should conform to.…”
Section: Negotiating Epistemic Value Through Biobrick Designmentioning
confidence: 99%
“…Are hESCs political and ethical objects or merely tools for stem cell therapies and research (cf. Eriksson and Webster, 2008)? Through deconstructions of these, we can understand more of how discourses serve to govern what is discussed and not discussed in media reporting.…”
Section: Subject Positions and Bio-identitiesmentioning
confidence: 99%
“…, Cyranoski 2007a;2007b). However, no consensus has been reached on whether these two types of pluripotent stem cells can be treated interchangeably, and no agreed-upon criteria for assessing their interchangeability are available (Eriksson and Webster 2008). For this reason, the therapeutic usefulness of iPS cells is yet to be confirmed, and in some western countries these cells are considered as the tools for basic research or modeling diseases in a laboratory, rather than the sources for RM (Hauskeller and Weber 2011).…”
Section: Introductionmentioning
confidence: 99%